No profile data available.
Anixa Biosciences, Inc. (ANIX) is a healthcare company in the additional cancer treatment drugs industry, based in San Jose, United States, with about 4 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$10.93 million. In Q3 2026 (the quarter ended July 31, 2026) revenue was $0. Its market capitalization was $100.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended October 31, 2025; market data as of October 9, 2026.
, a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Anixa Biosciences reported $0 in revenue for fiscal year 2025. In Q3 2026 revenue was $0.
$100.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include PMV Pharmaceuticals, Inc. (PMVP), Black Diamond Therapeutics, Inc. (BDTX), Corbus Pharmaceuticals Holdings, Inc. (CRBP), PDS Biotechnology Corporation (PDSB).